Rationale and Design of the Randomized Bayesian Multicenter COME-TAVI Trial in Patients With a New Onset Left Bundle Branch Block
Lena Rivard,Isabelle Nault,Andrew D Krahn,Benoit Daneault,Jean-Francois Roux,Madhu Natarajan,Jeffrey S Healey,Kenneth Quadros,Roopinder K Sandhu,Remi Kouz,Isabelle Greiss,Peter Leong-Sit,Jean Baptiste Gourraud,Walid Ben Ali,Anita Asgar,Martin Aguilar,Raoul Bonan,Julia Cadrin-Tourigny,Raymond Cartier,Jean-Francois Dorval,Marc Dubuc,Nicolas Dürrleman,Katia Dyrda,Peter Guerra,Marina Ibrahim,Reda Ibrahim,Laurent Macle,Blandine Mondesert,Emmanuel Moss,Alexandre Raymond-Paquin,Denis Roy,Rafik Tadros,Bernard Thibault,Mario Talajic,Anna Nozza,Marie-Claude Guertin,Paul Khairy
DOI: https://doi.org/10.1016/j.cjco.2023.05.009
2023-07-13
CJC Open
Abstract:Patients with new-onset left bundle branch block (LBBB) after transcatheter aortic valve implantation (TAVI) are at risk of developing delayed high-degree atrioventricular block. Management of new-onset LBBB post-TAVI remains controversial. In the Comparison of a Clinical Monitoring Strategy Versus Electrophysiology-Guided Algorithmic Approach in Patients With a New LBBB After TAVI (COME-TAVI) trial, consenting patients with new-onset LBBB that persists on day 2 after TAVI, meeting exclusion/inclusion criteria, are randomized to an electrophysiological study (EPS)-guided approach or 30-day electrocardiographic monitoring. In the EPS-guided approach, patients with a His to ventricle (HV) interval ≥ 65 ms undergo permanent pacemaker implantation. Patients randomized to noninvasive monitoring receive a wearable continuous electrocardiographic recording and transmitting device for 30 days. Follow-up will be performed at 3, 6, and 12 months. The primary endpoint is a composite outcome designed to capture net clinical benefit. The endpoint incorporates major consequences of both strategies in patients with new-onset LBBB after TAVI, as follows: (i) sudden cardiac death; (ii) syncope; (iii) atrioventricular conduction disorder requiring a pacemaker (for a class I or IIa indication); and (iv) complications related to the pacemaker or EPS. The trial incorporates a Bayesian design with a noninformative prior, outcome-adaptive randomization (initially 1:1), and 2 prespecified interim analyses once 25% and 50% of the anticipated number of primary endpoints are reached. The trial is event-driven, with an anticipated upper limit of 452 patients required to reach 77 primary outcome events over 12 months of follow-up. In summary, the aim of this Bayesian multicentre randomized trial is to compare 2 management strategies in patients with new-onset LBBB post-TAVI-an EPS-guided approach vs noninvasive 30-day monitoring. Trial registration number: NCT03303612.